Pharmacokinetics and Exposure-Response Relationship of Belimumab Administered Subcutaneously to SLE Patients

被引：0
|
作者：
Struemper, Herbert [1 ]
Thapar, Mita [2 ]
Gordon, David [3 ]
Roth, David [3 ]
机构：
[1] PAREXEL, Quantitat Clin Dev, Durham, NC USA
[2] ICON, Marlow, Bucks, England
[3] GSK, Philadelphia, PA USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2016年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
756
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Predicted Chronic Exposure and Dose Selection for Belimumab Administered Subcutaneously to SLE Patients
    Struemper, Herbert
    Roth, David
    Gordon, David
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S292 - S292
  • [2] Bioavailability, Pharmacokinetics, and Safety of Belimumab Administered Subcutaneously in Healthy Subjects
    Cai, Wendy
    Chen, Cecil
    Zhong, Z. John
    Freimuth, William W.
    Lewis, William
    Subich, David
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S267 - S267
  • [3] Bioavailability, Pharmacokinetics, and Safety of Belimumab Administered Subcutaneously in Healthy Subjects
    Cai, Wendy W.
    Fiscella, Michele
    Chen, Cecil
    Zhong, Z. John
    Freimuth, William W.
    Subich, David C.
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2013, 2 (04): : 349 - 357
  • [4] Pharmacokinetics and Exposure-response of Intravenous Belimumab in Children with Systemic Lupus Erythematosus
    Dimelow, Richard
    Ji, Beulah
    Struemper, Herbert
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [5] Inter-regional pharmacokinetics and exposure-response analyses of belimumab in patients with system lupus erythematosus
    Wu, Junyi
    Zhou, Xuan
    Dimelow, Richard
    Marshall, Scott
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024,
  • [6] Population Pharmacokinetics and Exposure-Response Relationship of Carfilzomib in Patients With Multiple Myeloma
    Ou, Ying
    Doshi, Sameer
    Anh Nguyen
    Jonsson, Fredrik
    Aggarwal, Sanjay
    Rajangam, Kanya
    Dimopoulos, Meletios A.
    Stewart, A. Keith
    Badros, Ashraf
    Papadopoulos, Kyriakos P.
    Siegel, David
    Jagannath, Sundar
    Vij, Ravi
    Niesvizky, Ruben
    Graham, Richard
    Visich, Jenn
    JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 57 (05): : 663 - 677
  • [7] Population Pharmacokinetics and Exposure-Response Relationship of Zimberelimab in Chinese Patients with Advanced Tumors
    Yang, Fang
    Lu, Yongying
    Bai, Lihui
    Deng, Chenhui
    Liu, Zhen
    Sun, Zhihua
    Li, Li
    Wang, Shicong
    Zhou, Li
    Feng, Haifeng
    Yan, Shaoyu
    Zhu, Jiman
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2024, 13 (08): : 897 - 906
  • [8] Everolimus pharmacokinetics and exposure-response relationship in Japanese patients with advanced breast cancer
    Hirabatake, Masaki
    Mizuno, Tomoyuki
    Kato, Hironori
    Hashida, Tohru
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [9] Population Pharmacokinetics and Exposure-Response Relationship of Intravenous and Subcutaneous Abatacept in Patients With Rheumatoid Arthritis
    Li, Xiaohui
    Roy, Amit
    Murthy, Bindu
    JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 59 (02): : 245 - 257
  • [10] Population pharmacokinetics and exposure-response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias
    Singh, Renu
    Mehrotra, Shailly
    Gopalakrishnan, Mathangi
    Gojo, Ivana
    Karp, Judith E.
    Greer, Jacqueline M.
    Chen, Alice
    Piekarz, Richard
    Kiesel, Brian F.
    Gobburu, Jogarao
    Rudek, Michelle A.
    Beumer, Jan H.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 83 (02) : 319 - 328
12345